Close Menu

Melanoma

News and reporting on melanoma.

The skin cancer diagnostics company said it delivered 5 percent fewer DecisionDx-Melanoma test results in Q4 2020 than in the previous year's fourth quarter.

The firm expects to increase commercial coverage for its pigmented lesion assay for melanoma while widening its pipeline to diagnose other varieties of skin cancer.

In a survey, analysts found that reimbursement and test awareness were major barriers to driving adoption of the firm's assay for identifying skin cancer.

Of the 32 companies in the index, 21 firms saw their stock prices increase, while 11 firms' share prices decreased. 

The investment bank highlighted the technology underlying DermTech's non-invasive, skin patch-based melanoma test as key to its future growth.

A bi-weekly listing of recent local coverage determinations from Medicare Administrative Contractors.

The skin cancer diagnostics company said it delivered 7 percent more DecisionDx-Melanoma test results in Q3 2020 than in the previous year's third quarter.

The tests are covered when the patient has a personal history of melanoma and the test has demonstrated clinical and analytical validity.

A bi-weekly listing of recent local coverage determinations from Medicare Administrative Contractors.

The general LCD is covered for patients with a personal history of melanoma undergoing workups or being evaluated for treatment without metastatic disease.

Pages